Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells

被引:254
作者
Ladoire, Sylvain [1 ,2 ]
Arnould, Laurent [2 ]
Apetoh, Lionel [3 ]
Coudert, Bruno [2 ]
Martin, Francois [1 ]
Chauffert, Bruno [1 ,2 ]
Fumoleau, Pierre [2 ]
Ghiringhelli, Francois [1 ,2 ,3 ]
机构
[1] INSERM, Ctr Rech 866, Ctr Georges Francois Leclerc, Fac Med, F-21000 Dijon, France
[2] INSERM, Ctr Rech 866, Ctr Reg Lutte Contre Canc, F-21000 Dijon, France
[3] Inst Gustave Roussy, Villejuif, France
关键词
D O I
10.1158/1078-0432.CCR-07-4491
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we evaluated CD3 and CD8 infiltrates, and the Foxp3 immunosuppressive T cells. Experimental Design: CD3(+), CD8(+), and Foxp3(+) cell infiltrates were detected by immunohistochemistry in a series of 56 breast cancer patients before and after the end of neoadjuvant chemotherapy. Results: Poor prognostic factors (negative hormonal receptors, high tumor grade, and nodal involvement) were associated with a significantly higher number of CD3, CD8, and Foxp3 infiltrates before the beginning of chemotherapy, Chemotherapy resulted in a decrease in Foxp3 infiltrates, whereas the level of CD8 and CD3 infiltrates remained unchanged. Pathologic complete responses (pCR) had a drastic decrease of Foxp3(+) cells, whereas these cells remained elevated in nonresponders. A cutoff criterion that combined high CD8 infiltration and no Foxp3 cell infiltration on surgical specimens is associated with pCR with a sensitivity of 75% and a specificity of 93%. The infiltrate of cytotoxic TiA1 and granzyme B - positive cells was dramatically enhanced after chemotherapy only in patients with pCR. By multivariate analysis, association of a high CD8 infiltration and no Foxp3 infiltration on final histologic specimens were independently associated with pCR. Conclusion: These findings indicate that pCR to neoadjuvant chemotherapy is associated with an immunologic profile combining the absence of immunosuppressive Foxp3 cells and the presence of a high number of CD8 T cells and cytotoxic cells. These results argue for the induction of an antitumor immune response by chemotherapy.
引用
收藏
页码:2413 / 2420
页数:8
相关论文
共 32 条
[1]  
Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131
[2]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[3]   Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].
Arnould, L ;
Gelly, M ;
Penault-Llorca, F ;
Benoit, L ;
Bonnetain, F ;
Migeon, C ;
Cabaret, V ;
Fermeaux, V ;
Bertheau, P ;
Garnier, J ;
Jeannin, JF ;
Coudert, B .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267
[4]   Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].
Bates, Gaynor J. ;
Fox, Stephen B. ;
Han, Cheng ;
Leek, Russell D. ;
Garcia, Jose F. ;
Harris, Adrian L. ;
Banham, Alison H. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380
[5]  
BLACK MM, 1956, AM J CLIN PATHOL, V26, P250
[6]   Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death [J].
Casares, N ;
Pequignot, MO ;
Tesniere, A ;
Ghiringhelli, F ;
Roux, S ;
Chaput, N ;
Schmitt, E ;
Hamai, A ;
Hervas-Stubbs, S ;
Obeid, M ;
Coutant, F ;
Métivier, D ;
Pichard, E ;
Aucouturier, P ;
Pierron, G ;
Garrido, C ;
Zitvogel, L ;
Kroemer, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1691-1701
[7]   INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE [J].
CHEVALLIER, B ;
ROCHE, H ;
OLIVIER, JP ;
CHOLLET, P ;
HURTELOUP, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03) :223-228
[8]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[9]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992
[10]   CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner [J].
Ghiringhelli, F ;
Ménard, C ;
Terme, M ;
Flament, C ;
Taieb, J ;
Chaput, N ;
Puig, PE ;
Novault, S ;
Escudier, B ;
Vivier, E ;
Lecesne, A ;
Robert, C ;
Blay, JY ;
Bernard, J ;
Caillat-Zucman, S ;
Freitas, A ;
Tursz, T ;
Wagner-Ballon, O ;
Capron, C ;
Vainchencker, W ;
Martin, F ;
Zitvogel, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (08) :1075-1085